<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02548611</url>
  </required_header>
  <id_info>
    <org_study_id>GE IDE MucT002-14</org_study_id>
    <nct_id>NCT02548611</nct_id>
  </id_info>
  <brief_title>Comparison of Loading Strategies With Antiplatelet Drugs in Patients Undergoing Elective Coronary Intervention</brief_title>
  <acronym>SASSICAIA</acronym>
  <official_title>Intensified Loading With Prasugrel Versus Standard Loading With Clopidogrel in Invasive-treated Patients With Biomarker-Negative Angina Pectoris</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Klinikum der Universitaet Muenchen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Klinikum der Universitaet Muenchen</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Use of high loading doses of clopidogrel (antiplatelet drug) just before coronary
      interventions is associated with improved outcomes after coronary stenting. However the onset
      of platelet inhibition after clopidogrel loading takes 2 to 4 hours and its action if very
      variable. A way to overcome this limitation is loading with a more potent antiplatelet drug
      such as prasugrel. Therefore in the current study the investigators want to compare loading
      with 60 mg prasugrel (potent antiplatelet drug) and loading with clopidogrel (standard drug)
      in patients undergoing elective coronary intervention.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with stable or clinically unstable (biomarker-negative) angina pectoris who are in
      need of coronary intervention will be randomly assigned in one of the treatment strategies -
      60 mg of prasugrel or 600 mg clopidogrel just prior to percutaneous coronary intervention
      (PCI). After PCI all patients will receive clopidogrel 75 mg/d as per standard. The patients
      will be monitored throughout a 30-day time frame and ischemic and bleeding events will be
      recorded. The study is powered to show the superiority of single-dose 60 mg prasugrel over
      single-dose 600 mg clopidogrel regarding the ischemic complications at 30-day follow-up.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Due to low recruitment
  </why_stopped>
  <start_date type="Actual">September 2015</start_date>
  <completion_date type="Actual">November 2018</completion_date>
  <primary_completion_date type="Actual">August 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Combined ischemic events</measure>
    <time_frame>30 days</time_frame>
    <description>Combined outcome of all-cause death, any myocardial infarction (MI), stent thrombosis, urgent revascularization and stroke</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Bleeding</measure>
    <time_frame>30 days</time_frame>
    <description>Academic Research Consortium ≥2 bleeding and TIMI classification</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peri-PCI MI Type 4a</measure>
    <time_frame>30 days</time_frame>
    <description>according to Third Universal Definition of MI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All-cause death</measure>
    <time_frame>30 days</time_frame>
    <description>mortality</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Any myocardial infarction</measure>
    <time_frame>30 days</time_frame>
    <description>according to SASSICAIA protocol definition</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stent thrombosis</measure>
    <time_frame>30 days</time_frame>
    <description>according to Academic Research Consortium criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urgent vessel revascularization</measure>
    <time_frame>30 days</time_frame>
    <description>revascularization related to symptoms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>cerebro-vascular events</measure>
    <time_frame>30 days</time_frame>
    <description>stroke and TIA</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">795</enrollment>
  <condition>Angina Pectoris</condition>
  <arm_group>
    <arm_group_label>Prasugrel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>single-dose loading with 60 mg of prasugrel pre PCI</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Clopidogrel</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>loading with 600 mg of clopidogrel pre PCI</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prasugrel</intervention_name>
    <description>see arm description</description>
    <arm_group_label>Prasugrel</arm_group_label>
    <other_name>Efient</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clopidogrel</intervention_name>
    <description>see arm description</description>
    <arm_group_label>Clopidogrel</arm_group_label>
    <other_name>Iscover, Plavix</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with biomarker negative stable or unstable angina pectoris

          -  Written informed consent

          -  In women with childbearing potential a pregnancy test is obligatory

        Exclusion Criteria:

          -  Age &lt; 18 years and &gt;80 years

          -  ST-elevation MI

          -  Elevated cardiac biomarkers

          -  Subjects with known contraindications to clopidogrel treatment, which are
             hypersensitivity to the drug substance or any component of the product and active
             pathological bleeding such as peptic ulcer or intracranial hemorrhage and with known
             severe liver disease (Child Pugh Class C)

          -  Subjects with known contraindications to prasugrel treatment, which are
             hypersensitivity to the drug substance or any component of the product, active
             pathological bleeding such as peptic ulcer or intracranial hemorrhage and a history of
             prior transient ischemic attack (TIA) or stroke and with known severe liver disease
             (Child Pugh Class C)

          -  Chronic therapy on potent P2Y12 receptor inhibitors (ticagrelor, prasugrel)

          -  Pre-treatment with a loading dose of either clopidogrel, prasugrel or ticagrelor

          -  Simultaneous participation in another clinical trial that involves the administration
             of an investigational medicinal drug within 30 days prior to the start of this
             clinical trial

          -  Major surgeries in the last 6 weeks and planned surgeries within the next 6 weeks (per
             decision of the treating physician)

          -  Active bleeding

          -  Known or persistent abuse of medication, drugs or alcohol

          -  Current or planned pregnancy or nursing women, women 90 days after childbirth. Females
             of childbearing potential, who do not use and are not willing to use medically
             reliable methods of contraception for the entire study duration (such as oral,
             injectable, or implantable contraceptives, or intrauterine contraceptive devices)
             unless they are surgically sterilized / hysterectomized or there are any other
             criteria considered sufficiently reliable by the investigator in individual cases
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Julinda Mehilli, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Munich</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Universitäts-Herzzentrum Freiburg, Bad Krozingen</name>
      <address>
        <city>Freiburg</city>
        <state>Bad Krozingen</state>
        <zip>79189</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Munich University Hospital</name>
      <address>
        <city>Munich</city>
        <state>Bavaria</state>
        <zip>81377</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Deutsches Herzzentrum Muenchen</name>
      <address>
        <city>Munich</city>
        <zip>80636</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Bogenhausen</name>
      <address>
        <city>Munich</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Heart Center Balatonfüred and Heart and Vascular Center</name>
      <address>
        <city>Balatonfüred</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Hungary</country>
  </location_countries>
  <link>
    <url>https://www.ahajournals.org/doi/full/10.1161/CIRCINTERVENTIONS.119.008649?url_ver=Z39.88-2003&amp;rfr_id=ori%3Arid%3Acrossref.org&amp;rfr_dat=cr_pub++0pubmed&amp;</url>
    <description>Study result publication</description>
  </link>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>September 10, 2015</study_first_submitted>
  <study_first_submitted_qc>September 11, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 14, 2015</study_first_posted>
  <last_update_submitted>July 15, 2020</last_update_submitted>
  <last_update_submitted_qc>July 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Klinikum der Universitaet Muenchen</investigator_affiliation>
    <investigator_full_name>Prof. Dr. Julinda Mehilli</investigator_full_name>
    <investigator_title>Prof. Dr. med.</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Angina Pectoris</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clopidogrel</mesh_term>
    <mesh_term>Prasugrel Hydrochloride</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

